MedDay is changing how neurological treatments are found, with a future-focused, dynamic and rigorous approach

Our Story

The story of MedDay began in 2011, when Frédéric Sedel, MD, PhD, a neurologist and neuroscientist met with Guillaume Brion, an entrepreneur with experience in drug development. Both used their expertise and worked together to create MedDay, a pioneering biopharmaceutical company with a unique approach focusing on neurometabolism.

Alongside its main program in Progressive Multiple Sclerosis, MedDay has laid the foundation to become the global leader in the neurometabolic field by investing in SPECMET, its innovative discovery platform. SPECMET will allow MedDay to embark on a more ambitious quest to find therapies for important neurological diseases with metabolic abnormalities.

MedDay has a new and unique perspective: exploring metabolic pathways in people affected by nervous systems disorders in order to develop our growing pipeline of promising neurometabolic programs.

 

Investors

MedDay is supported by a group of leading investors who share a collective vision to create a business that delivers medicines to patients in areas of high unmet medical need. In total, MedDay raised €42 million of funding to support the global development of the company.

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, the firm brings together highly experienced investment professionals from all over Europe, the US and China. Over the past 40 years, the firm has financed and supported almost 500 companies.

Bpifrance is a French public investment bank, focused on the development and funding of companies. It is a subsidiary of the Caisse des Dépôts and the French State and supports companies from start-up to their listing on the stock market, through credit, guarantees and equity.

Andera Partners is an accelerator for growth and innovation, dedicated to investments in biotechs and small and medium sized enterprises (SMEs). Created in 2001 as part of the Edmond de Rothschild Group, Andera Partners manages over €2 billion of private equity funds in 2018.

Key dates

2011 Company inception – Founded by Dr. Frédéric Sedel and Dr. Guillaume Brion
2013 Series A financing €8 million
2014 1st patent granted in the US and in EU
2016 Series B financing €34 million
2017 Acquisition of the company “Profilomic SA” to strengthen SPECMET, MedDay’s metabolomics research platform
2018 Christian Chavy appointed as MedDay's new Chief Executive Officer

Origin of the name MedDay

Our company’s name MedDay refers to the «mayday» distress signal, coined by the aeronautics industry in 1923, and derived from the French «m’aider» (‘help me’), a shortened form of «venez m’aider» (‘come and help me’).

In accordance with our name, MedDay, we aim to show our willingness to respond to the needs of patients with neurological diseases, their families and their doctors who currently have limited or no therapeutic options.

The SOS morse code that we use to underline our logo, reminds us every day of our mission.